63465 A Comparison of the Risk of Major Cardiovascular Events, Venous Thromboembolism, Serious Infections, and Malignancies Among Patients With Vitiligo in the United States Using Real-World Data
Recommended Citation
King B, Eleftheriadou V, Bristow CC, Conrad DM, Elbuluk N, Wolkerstorfer A, Lui H, Yue E, Ofori S, Passeron T, Hamzavi I. 63465 A Comparison of the Risk of Major Cardiovascular Events, Venous Thromboembolism, Serious Infections, and Malignancies Among Patients With Vitiligo in the United States Using Real-World Data. J Am Acad Dermatol 2025; 93:AB8.
Document Type
Conference Proceeding
Publication Date
9-1-2025
Publication Title
J Am Acad Dermatol
Abstract
Different inflammatory diseases have different comorbidities and risk of adverse outcomes. This retrospective US analysis of Optum Clinformatics Data Mart claims evaluated the risk factors and incidence of outcomes including major cardiovascular events (MACE), venous thromboembolism (VTE), serious infections, malignancy excluding nonmelanoma skin cancer (NMSC), and NMSC. Eligibility criteria included age ≥12 years; a diagnosis of vitiligo, rheumatoid arthritis (RA), or atopic dermatitis (AD) between January 2014–March 2023; and ≥365 days of continuous enrollment before cohort entry date. Patients with vitiligo were matched with controls 1:3 by age (±1 year), sex, calendar time, and visit type (outpatient/inpatient). Adjusted incidence rate ratios (aIRRs) comparing patients with vitiligo with matched controls and AD and RA cohorts were calculated using a Poisson regression model adjusted for baseline demographics, other autoimmune conditions, and cardiovascular risk factors. A total of 30,130 patients with vitiligo, 90,388 matched controls, 940,447 patients with AD, and 209,954 patients with RA were identified. Mean age was 54.3, 54.7, and 61.1 years for the vitiligo, AD, and RA cohorts, respectively. Patients with vitiligo had a lower prevalence of cardiovascular, VTE, and malignancy risk factors vs matched controls and RA and AD cohorts. Incidence rates (per 1000 person-years) of MACE, VTE, serious infections, malignancy excluding NMSC, and NMSC in the vitiligo cohort were 10.78, 4.71, 19.33, 14.67, and 11.56, respectively. Incidence rates for MACE, VTE, serious infections, and malignancy were significantly lower among patients with vitiligo vs matched controls (all aIRRs <0.85) and RA (all <0.87) and AD cohorts (all <0.93).
Volume
93
First Page
AB8
